What is Evolus Inc (EOLS)?
Evolus Inc is a specialty pharmaceutical company focused on aesthetic medicine. The company develops and commercializes products primarily for aesthetic indications, including neuromodulators used to temporarily improve the appearance of moderate to severe frown lines. Evolus operates within the healthcare sector, targeting medical professionals such as dermatologists, plastic surgeons, and other aesthetic practitioners. Its business model involves marketing and distributing products that cater to the growing demand for minimally invasive cosmetic treatments. The company emphasizes research and development to support product efficacy and safety, aligning with regulatory standards. Evolus also engages in educational initiatives to inform healthcare providers about aesthetic treatments and product applications. Headquartered in the United States, the company participates in a competitive market alongside other pharmaceutical and biotechnology firms specializing in aesthetic and therapeutic solutions. Evolus's activities contribute to the broader field of medical aesthetics, which encompasses various treatments aimed at enhancing physical appearance through non-surgical methods.
Evolus Inc Stock Price Today: Live Overview
The price today is shaped by trading momentum, with Evolus Inc priced at $4.68. Its price has moved within a range of $4.62 to $4.84, corresponding to a daily change of 0%.
FAQ: Evolus Inc (EOLS)
What is the current price of EOLS stock?
The current price is $4.68.
Does EOLS pay dividends?
Evolus Inc does not pay dividends.
Does EOLS have a formal corporate presence or regional headquarters in the UAE?
Evolus Inc operates in the UAE only through partners and distributors without a direct office or subsidiary.
What is EOLS best known for?
Evolus Inc is most famous for its aesthetic neuromodulator products.
What assets are typically shown together with EOLS?
Commonly shown alongside EOLS: Invivyd Inc., Ionis Pharmaceuticals, CytomX Therapeutics Inc
Latest shares articles



